JP2020516663A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516663A5 JP2020516663A5 JP2019556183A JP2019556183A JP2020516663A5 JP 2020516663 A5 JP2020516663 A5 JP 2020516663A5 JP 2019556183 A JP2019556183 A JP 2019556183A JP 2019556183 A JP2019556183 A JP 2019556183A JP 2020516663 A5 JP2020516663 A5 JP 2020516663A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydronaphthalene
- dioxo
- methoxy
- methylidene
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762486033P | 2017-04-17 | 2017-04-17 | |
| US62/486,033 | 2017-04-17 | ||
| PCT/US2018/027786 WO2018194976A1 (en) | 2017-04-17 | 2018-04-16 | Prevention and reversal of inflammation induced dna damage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020516663A JP2020516663A (ja) | 2020-06-11 |
| JP2020516663A5 true JP2020516663A5 (enExample) | 2021-04-30 |
Family
ID=63856081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556183A Pending JP2020516663A (ja) | 2017-04-17 | 2018-04-16 | 炎症によって誘起されるｄｎａ損傷の阻止及び回復 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20190117602A1 (enExample) |
| EP (1) | EP3440047A4 (enExample) |
| JP (1) | JP2020516663A (enExample) |
| CA (1) | CA3060266A1 (enExample) |
| WO (1) | WO2018194976A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020514349A (ja) * | 2017-03-20 | 2020-05-21 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 癌の処置のための併用治療剤におけるａｐｅ１／ｒｅｆ−１阻害剤の使用 |
| JP7266304B2 (ja) | 2017-04-21 | 2023-04-28 | ユニヴァーシティー オブ タスマニア | 治療化合物および方法 |
| EP3897601A4 (en) * | 2018-12-17 | 2022-08-31 | Indiana University Research And Technology Corporation | TREATMENT OF GASTROINTESTINAL DISEASES AND THEIR SYMPTOMS |
| JP2025529483A (ja) | 2022-09-14 | 2025-09-04 | オーパス・ジェネティクス・インコーポレイテッド | Ａｐｘ３３３０の塩及びエステルならびにその治療的使用 |
| CN119097711A (zh) * | 2024-09-11 | 2024-12-10 | 山东大学齐鲁医院 | Ape1抑制剂在制备治疗鼻窦炎药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0801949A1 (en) * | 1996-04-15 | 1997-10-22 | Eisai Co., Ltd. | Hypoglycemic quinone derivative |
| JPH1067653A (ja) * | 1996-06-17 | 1998-03-10 | Eisai Co Ltd | 関節疾患治療剤 |
| EP0813866A3 (en) * | 1996-06-17 | 1999-01-20 | Eisai Co., Ltd. | Therapeutic agent for joint diseases |
| US20030229004A1 (en) | 2002-03-20 | 2003-12-11 | Pangene Corporation | Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors |
| US8710095B2 (en) * | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| BRPI0817293A2 (pt) * | 2007-09-26 | 2015-06-16 | Univ Indiana Res & Tech Corp | Derivado de benzoquinona e3330 em combinação com agentes quimioterapêuticos para o tratamento de câncer e angiogenese |
| KR20110103442A (ko) | 2008-12-23 | 2011-09-20 | 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 | 염증 표적화 입자 |
| GB201020397D0 (en) | 2010-12-02 | 2011-01-12 | Univ Nottingham | Compounds |
| WO2012148889A1 (en) | 2011-04-28 | 2012-11-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of human apurinic/apyrimidinic endonuclease 1 |
| MX357284B (es) * | 2011-05-26 | 2018-07-04 | Univ Indiana Res & Tech Corp | Compuestos de quinona para tratar enfermedades mediadas por ape1. |
| US20140128398A1 (en) * | 2011-06-03 | 2014-05-08 | Indiana University Research And Technology Corporation | Compounds, compositions and methods for treating oxidative dna damage disorders |
| CN107184572B (zh) | 2017-03-09 | 2020-07-28 | 中山大学 | 一种ape1抑制剂及其在制备用于治疗肿瘤和血管异常增生性疾病药物中的应用 |
-
2018
- 2018-04-16 EP EP18788150.3A patent/EP3440047A4/en not_active Withdrawn
- 2018-04-16 JP JP2019556183A patent/JP2020516663A/ja active Pending
- 2018-04-16 US US16/092,816 patent/US20190117602A1/en not_active Abandoned
- 2018-04-16 CA CA3060266A patent/CA3060266A1/en active Pending
- 2018-04-16 WO PCT/US2018/027786 patent/WO2018194976A1/en not_active Ceased
-
2020
- 2020-04-16 US US16/850,436 patent/US11351130B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023533464A5 (enExample) | ||
| JP2020533315A5 (enExample) | ||
| JP2020502157A5 (enExample) | ||
| Zorzi et al. | A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium | |
| HRP20220619T1 (hr) | Postupci za liječenje ar+ raka dojke | |
| JP2018514549A5 (enExample) | ||
| JP2014532647A5 (enExample) | ||
| JP2016513097A5 (enExample) | ||
| JP2019508476A5 (enExample) | ||
| JP2007536311A5 (enExample) | ||
| JP2016515586A5 (enExample) | ||
| JP2016525097A5 (enExample) | ||
| JP2019522032A5 (enExample) | ||
| RU2010151660A (ru) | Способы лечения множественной миеломы | |
| RU2020109376A (ru) | Применение антагонистов рецептора ep4 для лечения nash- ассоциированного рака печени | |
| RU2008152341A (ru) | Применение аллопуринола для лечения ладонно-подошвенной эритродизестезии | |
| Gupta et al. | Combating inadequate anesthesia in periapical infections, with sodium bicarbonate: a clinical double blind study | |
| JP2023525100A5 (enExample) | ||
| JP2020529995A5 (enExample) | ||
| RU2017102319A (ru) | Прерывистое введение ингибитора mdm2 | |
| JP2005505539A (ja) | パーキンソン病の治療のためのｃｂ１受容体アンタゴニストと、脳のドーパミン作用性神経伝達を活性化する製品を含む組成物 | |
| JP2023531675A5 (enExample) | ||
| JP2006502132A5 (enExample) | ||
| JP2024503727A5 (enExample) | ||
| CL2024001520A1 (es) | Nueva composición farmacéutica oral y régimen de dosificación para la terapia de enfermedades pulmonares intersticiales |